Redeye is growing more confident on the case following last Friday’s announcement of a significant o...
Redeye initiates coverage of Circio (previously Targovax), which has a new focus on circular RNA tec...
2023 is soft but BTS rarely wastes a crisis and is prepared for 2024 Pricing, software and talent mi...
The main point is the confirmation of the statistically significant eGFR benefits and the reduction ...
PolarCool kommunicerade igår den 28 september att bolaget tillsammans med United Rugby Championship ...
Redeye is encouraged to see that LKAB is extending its contract with Railcare through 2024.
Redeye holds a positive view of TH1NG’s acquisition of IIOOTE, seeing its potential to strengthen TH...
Redeye comments on the second published study in two days regarding the Skin Barrier field from Scib...
Redeye updates its estimates ahead of the Q3 report (due 27 October) with a small downward adjustmen...
The gap-fill process will allow Biovica to secure a Medicare (CMS) code and a preliminary price as o...
Bolaget har spännande prospektering på gång, vilket vid ett lyckosamt utförande kan ge ett bra värde...
Redeye comments on today’s news from SDS, where the company announced the outcome of the directed sh...
Value accretive shift in strategy Directed share issue of SEK 150m Fair value range up to SEK 9-15 (...
Q3e sales SEK 49m, -14% y-o-y, +17% q-o-q; EBIT SEK -3m (-2m) Change of analyst: '23e-'25e sales dow...
Redeye is encouraged by the publication of the clinical results from a study at the University Child...
EcoRub meddelade nyligen att de lanserar färgade återvunna TPE-material och material för 3D-printing...
Redeye is once again positively surprised that Arise will see further revenue recognition and receiv...
The Norwegian competitor Q-FREE, listed on the Oslo stock exchange, has a bid placed on it by Junipe...
• Q3 report due 25 Oct • Q3'23e net sales SEK 167m, EBITA SEK 22m • Share trading at 6x Factset cons...
Redeye welcomes the discontinuation of the cranial implant, freeing up resources for the company to ...
